Filing Date |
T Date |
Ticker |
Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
#f |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
11/3/25 16:05 | 10/30/25 | TWST | Health | BioPrd | Biological Products, (No Diag | Cho Dennis | CA | O | See Rema | 7 | S | -362 | 31.16 | 0 | -12 | 122 | D | |||||||||||||||
11/3/25 16:05 | 10/30/25 | TWST | Health | BioPrd | Biological Products, (No Diag | Finn Patrick John | CA | O | P,COO | 5 | S | -1,441 | 31.57 | 0 | -46 | 269 | D | |||||||||||||||
11/3/25 16:05 | 10/30/25 | TWST | Health | BioPrd | Biological Products, (No Diag | Green Paula | CA | O | SVP of H | 6 | S | -582 | 31.30 | 0 | -19 | 143 | D | |||||||||||||||
11/3/25 16:05 | 10/30/25 | TWST | Health | BioPrd | Biological Products, (No Diag | Leproust Emily M. | CA | DO | CEO | 6 | S.d | -2,185 | 31.27 | 0 | -70 | 739 | D | |||||||||||||||
11/3/25 16:05 | 10/30/25 | TWST | Health | BioPrd | Biological Products, (No Diag | Laponis Adam | CA | O | CFO | 4 | S.m | -563 | 31.57 | 0 | -18 | 111 | D | |||||||||||||||
11/3/25 16:05 | 10/30/25 | TWST | Health | BioPrd | Biological Products, (No Diag | Werner Robert F. | CA | O | Chief Ac | 5 | S | -133 | 30.46 | 0 | -4 | 51 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |